These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29916008)

  • 1. Heterogeneity in Outcomes of Pathologic T1-2N1 Breast Cancer After Mastectomy: Looking Beyond Locoregional Failure Rates.
    Bazan JG; Majithia L; Quick AM; Wobb JL; Terando AM; Agnese DM; Farrar W; White JR
    Ann Surg Oncol; 2018 Aug; 25(8):2288-2295. PubMed ID: 29916008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes.
    He ZY; Wu SG; Zhou J; Li FY; Lin Q; Lin HX; Sun JY
    PLoS One; 2015; 10(3):e0119105. PubMed ID: 25781605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.
    Muhsen S; Moo TA; Patil S; Stempel M; Powell S; Morrow M; El-Tamer M
    Ann Surg Oncol; 2018 Jul; 25(7):1912-1920. PubMed ID: 29564588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1-T2 and One to Three Positive Lymph Nodes.
    Huo D; Hou N; Jaskowiak N; Winchester DJ; Winchester DP; Yao K
    Ann Surg Oncol; 2015 Dec; 22(13):4295-304. PubMed ID: 25820998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-mastectomy Radiation Therapy in Breast Cancer Patients with Nodal Micrometastases.
    Wu SP; Tam M; Shaikh F; Lee A; Chun J; Schnabel F; Guth A; Adams S; Schreiber D; Oh C; Gerber NK
    Ann Surg Oncol; 2018 Sep; 25(9):2620-2631. PubMed ID: 29987606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
    J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
    Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
    [No Abstract]   [Full Text] [Related]  

  • 8. Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era.
    Miyashita M; Tada H; Suzuki A; Watanabe G; Hirakawa H; Amari M; Kakugawa Y; Kawai M; Furuta A; Sato K; Yoshida R; Ebata A; Sasano H; Jingu K; Ohuchi N; Ishida T
    Surg Oncol; 2017 Jun; 26(2):163-170. PubMed ID: 28577722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
    Zhao JM; An Q; Sun CN; Li YB; Qin ZL; Guo H; Zeng X; Zhang YT; Wei LL; Han N; Sun SC; Zhang N
    Breast Cancer; 2021 Mar; 28(2):298-306. PubMed ID: 32940902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions.
    Wang S; Wen G; Tang Y; Yang Y; Jing H; Wang J; Zhang J; Zhao X; Sun G; Jin J; Song Y; Liu Y; Fang H; Zhang Y; Li Y
    BMC Cancer; 2020 Aug; 20(1):792. PubMed ID: 32838753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
    Wang X; Zhang L; Zhang X; Luo J; Wang X; Chen X; Yang Z; Mei X; Yu X; Zhang Z; Guo X; Shao Z; Ma J
    Breast Cancer Res Treat; 2021 Nov; 190(2):277-286. PubMed ID: 34490502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.
    Recht A; Comen EA; Fine RE; Fleming GF; Hardenbergh PH; Ho AY; Hudis CA; Hwang ES; Kirshner JJ; Morrow M; Salerno KE; Sledge GW; Solin LJ; Spears PA; Whelan TJ; Somerfield MR; Edge SB
    Pract Radiat Oncol; 2016; 6(6):e219-e234. PubMed ID: 27659727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
    Tendulkar RD; Rehman S; Shukla ME; Reddy CA; Moore H; Budd GT; Dietz J; Crowe JP; Macklis R
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e577-81. PubMed ID: 22560546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes.
    Moo TA; McMillan R; Lee M; Stempel M; Patil S; Ho A; El-Tamer M
    Ann Surg Oncol; 2013 Oct; 20(10):3169-74. PubMed ID: 23975289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nomogram predicting survival as a selection criterion for postmastectomy radiotherapy in patients with T1 to T2 breast cancer with 1 to 3 positive lymph nodes.
    Tang Y; Zhang YJ; Zhang N; Shi M; Wen G; Cheng J; Wang HM; Liu M; Wang XH; Guo QS; Wu HF; Ma CY; Jin J; Liu YP; Song YW; Fang H; Ren H; Wang SL; Li YX
    Cancer; 2020 Aug; 126 Suppl 16():3857-3866. PubMed ID: 32710662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer.
    Truong PT; Olivotto IA; Speers CH; Wai ES; Berthelet E; Kader HA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):797-804. PubMed ID: 14967436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumor and 1-3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases.
    Shen H; Zhao L; Wang L; Liu X; Liu X; Liu J; Niu F; Lv S; Niu Y
    Tumour Biol; 2016 May; 37(5):6465-75. PubMed ID: 26631044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: is there a role for radiation therapy?
    Cosar R; Uzal C; Tokatli F; Denizli B; Saynak M; Turan N; Uzunoglu S; Ozen A; Sezer A; Ibis K; Uregen B; Yurut-Caloglu V; Kocak Z
    Radiat Oncol; 2011 Mar; 6():28. PubMed ID: 21450076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for breast cancer patients with T1-2 tumor and 1-3 positive axillary nodes treated using total mastectomy without radiotherapy.
    Asaga S; Kinoshita T; Shiino S; Jimbo K; Takayama S
    Breast J; 2019 Jan; 25(1):26-33. PubMed ID: 30414218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.